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Abstract
Background: While conventional G-banded karyotyping still remains a gold standard in prenatal genetic diagnoses, 
the widespread adoption of array Comparative Genomic Hybridization (array CGH) technology for postnatal genetic 
diagnoses has led to increasing interest in the use of this same technology for prenatal diagnosis. We have investigated 
the value of our own designed DNA chip as a prenatal diagnostic tool for detecting submicroscopic deletions/
duplications and chromosome aneuploidies.
Methods: We designed a target bacterial artificial chromosome (BAC)-based aCGH platform (MacArray™ M-chip), 
which specifically targets submicroscopic deletions/duplications for 26 known genetic syndromes of medical 
significance observed prenatally. To validate the DNA chip, we obtained genomic DNA from 132 reference materials 
generated from patients with 22 genetic diseases and 94 clinical amniocentesis samples obtained for karyotyping.
Results: In the 132 reference materials, all known genomic alterations were successfully identified. In the 94 clinical 
samples that were also subjected to conventional karyotyping, three cases of balanced chromosomal aberrations were 
not detected by aCGH. However, we identified eight cases of microdeletions in the Yq11.23 chromosomal region that 
were not found by conventional karyotyping. This region harbors the DAZ gene, and deletions may lead to non-
obstructive spermatogenesis.
Conclusions: We have successfully designed and applied a BAC-based aCGH platform for prenatal diagnosis. This 
platform can be used in conjunction with conventional karyotyping and will provide rapid and accurate diagnoses for 
the targeted genomic regions while eliminating the need to interpret clinically-uncertain genomic regions.
Background
Speed and precision are two major requirements in pre-
natal chromosome analyses. Conventional G-banded
karyotyping remains the gold standard in prenatal genetic
diagnosis, but it is time-consuming and labor-intensive.
Routinely, about 10-14 days is required to obtain the
result and this may increase the patient's anxiety. To over-
come these limitations, rapid fluorescent in situ hybrid-
ization (FISH), quantitative fluorescent polymerase chain
reaction (QF-PCR), and multiplex ligation-dependent
probe amplification (MLPA) have been developed and are
widely used as adjuncts to conventional methods for
detecting common chromosome aneuploidies such as tri-
somies 21, 13, 18, X and Y [1-6]. However, only a few loci
may be tested at a time, so all those methods can usually
be performed only in a limited manner based on pheno-
type.
In addition, conventional G-banded karyotyping can
hardly detect small deletions and duplications that result
in serious clinical conditions such as congenital anoma-
lies, mental retardation and developmental delay during
the fetal stage as well as after birth. Recently, array com-
parative genomic hybridization (aCGH) has been used in
p r e n a t a l  a s  w e l l  a s  p o s t n a t a l  c l i n i c a l  c y t o g e n e t i c s  t o
detect submicroscopic chromosomal imbalances [7-9].
This technique gives rapid results and multiplex detec-
tion of both numerical and unbalanced structural abnor-
malities with much higher resolution and wider coverage
than conventional karyotyping and other molecular cyto-
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genetic techniques. Several types of platform with differ-
ent resolutions for aCGH have been developed. More
recently, genome-wide oligonucleotide aCGH chips with
several-kb resolutions have become commercially avail-
able. However, for clinical purposes, especially prenatal
diagnosis, these high-resolution whole-genome aCGH
chips are not adequate because of difficulties of interpre-
tation mainly resulting from benign copy number varia-
tions (CNVs), hybridization quality and cost. On the
other hand, targeted bacterial artificial chromosome
(BAC)-based aCGH methods have been successfully used
in prenatal diagnosis [7,10-12].
In this study, we have developed and evaluated a low
density BAC-array prenatal DNA chip targeted to 26
known genetic syndromes of medical significance, caused
by 19 microdeletions/duplications as well as numerical
changes in chromosomes 13, 18, 21, X and Y.
Methods
Subjects
T o validate the array, because we could not obtain four
microdeletion syndromes - Sotos syndrome, monosomy
1p36, SRY region of Yp and Kallmann syndrome - we
used 132 reference materials of 22 genetic disorders, 15
for microdeletions or duplications and 7 for chromosome
aneuploidies, as positive controls. The cell lines were pur-
chased from the Coriell Cell Resource http://ccr.cori-
ell.org/nigms/products/pdr.html.
For clinical application of the array, all protocols were
reviewed and approved by the Internal Review Board of
CHA General Hospital and written informed consent was
received from all participants. In total, 94 clinical samples
were admitted. Sample types and reasons for referral are
summarized in Table 1. During September 2007 through
July 2008, amniocenteses were performed at the 15th to
20th weeks of gestation on 94 pregnant women who vis-
ited CHA General Hospital, Korea. The mean age of the
pregnant women was 34.4 years.
For all positive controls and clinical samples, experi-
ments were performed blind to exclude biases. Cytoge-
netic analyses and aCGH were independently executed in
two different laboratories.
Cytogenetic analysis
Amniocytes were grown in Chang Medium® in situ (Irvine
Scientific, Santa Ana, CA) and in Bio-AMF-2 complete
medium (Biological Industries, Israel), with 5% CO2 in a
37°C incubator. All procedures including in situ culture,
harvesting, slide preparation and GTG-banding followed
routine protocols [13]. For each sample, more than 20
metaphases were examined.
Manufacture of BAC-mediated array CGH, MacArray™ 
M-chip
The MacArray™ M-chip was developed to detect the 19
microdeletion syndromes as well as numerical aberra-
tions (i.e. aneuploidies) in chromosomes 13, 18, 21, X and
Y. A total of 181 BAC clones were prepared from our
DNA BAC libraries (Macrogen, Korea) to design overlap-
ping probes that detected consecutive and consistent
alterations of the genome. All selected clones were two-
end sequenced using an ABI PRISM 3700 DNA Analyzer
(Applied Biosystems, USA), and their sequences were
blasted and mapped according to their positions. The
locus specificities of selected clones were confirmed indi-
vidually by removing multiple locus-binding clones under
standard FISH. Information about the 181 clones is
shown in Additional file 1 table S1.
The probes were dissolved in 50% DMSO (400~500 ng/
μl density) at 21~23°C and under 40~60% humidity. We
used Corning UltraGAPS (Corning, USA) for amine-
coated slides, Genemachines OmniGrid 100 (Digilab
Genomic Solutions, USA) for DNA spotting, and Tele-
Table 1: Indications for chromosome analyses in clinical cases admitted
Sample type  Indications*  No. of samples 
Amniotic fluid Advanced maternal age 42
Abnormal serum screening results 38
Abnormal ultrasonogram 12
Family history of genomic disorder or cytogenetic abnormalities 2
Pregnancy after artificial reproductive technology (intracytoplasmic 
sperm injection)
6
Rubella IgM positive 1
Others 3
Total 94
Some patients had two or more indicationsPark et al. BMC Medical Genetics 2010, 11:102
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cam SMP4 (Arrayit Corporation, USA) for pin. We fol-
lowed the general contact type spotter process. Each BAC
clone was represented on the array as triplicate spots.
DNA preparation and labeling for MacArray™ M-chip
Genomic DNAs were extracted using a Gentra Puregen
Cell kit (Qiagen Inc., German) from cell lines and clinical
samples. The DNAs in 85 of the amniotic fluid samples
were directly extracted, while DNAs in nine other cases
were extracted after culture. DNA concentration and
purity were measured by 1% agarose gel electrophoresis
and a NanoDrop ND-100 Full-spectrum UV/Vis Spectro-
photometer (Thermo Scientific, USA). Only samples with
both 260/280 and 260/230 ratios >1.7 were used for the
experiment. The labeling and hybridization protocols
described by Pinkel et al. [14] were followed with some
modifications, using a Bioprime labeling kit (Invitrogen
Carlsberg, CA, USA). Briefly, 21 μl solution containing
500 ng reference DNA or test DNA was mixed with ran-
dom primers solution and water in a BioPrime Array
CGH Labeling System Genomic labeling Module, incu-
bated for 5 min at 95°C, and subsequently cooled on ice.
After the addition of 5 μl 10 × dNTPs labeling mixture (1
mM dCTP, 2 mM dATP, 2 mM dGTP, 2 mM dTTP), 3 μl
1 mM Cy-3 or Cy-5 dCTP (GeneChem Inc., Daejeon,
Korea), and 40 U Klenow fragment in the BioPrime Array
CGH Labeling System Genomic labeling Module, the
mixture was gently mixed and incubated overnight at
3 7 ° C .  A d d i t i o n  o f  5  μ l  S t o p  B u f f e r  i n  B i o P r i m e  A r r a y
CGH Labeling System Genomic labeling Module termi-
nated the reaction. After labeling, unincorporated fluo-
rescent nucleotides were removed using the BioPrime
Array CGH Purification Module. In one tube, Cy3-
labeled sample DNAs and Cy5-labeled reference DNAs
were mixed and 50 μg human Cot-1 DNA (Invitrogen,
Carlsberg, CA, USA), 20 μl 3 M sodium acetate and 600
μl cold 100% ethanol were added to precipitate the DNA.
Array hybridization, imaging and data analysis
The pellet was resuspended in 30 μl hybridization solu-
tion containing 50% formamide, 10% dextran sulfate, 2×
SSC, 4% SDS and 200 μg yeast tRNA. The hybridization
solution was denatured for 10 min at 72°C and subse-
quently incubated for 1 h at 37°C to block repetitive
sequences. Hybridization was performed in slide cham-
bers for 48 h at 37°C. After post-hybridization washes,
the arrays were rinsed, spin-dried and scanned into two
16-bit TIFF image files using a GenePix 4200 a two-color
fluorescence scanner (MDS, Toronto, Canada). To deter-
mine the intensity of each spot, the scanned images were
analyzed with MacViewer™ M software (Macrogen, Inc.,
Korea). The log2-transformed fluorescence ratios were
calculated from background-subtracted median intensity
values. For each spot, we used 0.25 and -0.25 as thresh-
olds of gain and loss, respectively.
Fluorescent in situ hybridization (FISH)
Fluorescent in situ hybridization (FISH) was used to ver-
ify the microdeletion of Yq11.23, which indicates non-
obstructive spermatogenic failure, identified by the Mac-
Array™ M-chip. FISH probes for the region were gener-
ated from the human BAC clones RP11-214M24, RP11-
140H23, RP11-26B12 and RP11-539D10, purchased from
Abbott Laboratories. Bacterial culture and DNA prepara-
tions were performed according to the supplier's proto-
col. Purified BAC clone DNA (1 μg) was labeled with
spectrum-red dUTP using a Nick Translation Labeling
Kit (Abbott Laboratories, IL). FISH was performed using
a standard protocol.
Results
MacArray™ M-chip development
We designed a novel, low-density array CGH chip, the
MACROGEN MacArray™ M-chip, to detect not only ane-
uploidies but also micro-level chromosomal aberrations
sensitively (see Materials and Methods). Table 2 specifies
the characteristics of the 26 diseases (19 micro-deletions
and 7 aneuploidies) targeted by the MacArray™ M-chip.
Proficiency test using standard reference materials
We evaluated the feasibility of the MacArray™ M-chip
using commercially available standard reference materi-
als. We tested 132 samples bought from Coriell to evalu-
ate the detection of the 15 micro-deletions/duplications
and 7 aneuploidies. We successfully detected all these
aberrations. Four selected cases detected by the MacAr-
ray™ M-chip - 15q11-15q13 micro-deletion causing
Prader-Willi syndrome, 5p15.2 micro-deletion causing
cri-du-chat syndrome, Xp21.2 micro-deletion causing
Duchenne muscular dystrophy and 18p11.32~18q22.3
aneuploidy causing trisomy18 are shown in figure 1. The
sample numbers for each target are different from each
other, and reference materials for Kallmann syndrome,
Sotos syndrome, monosomy 1p36 and the SRY region of
Yp were not available. The overall results are presented in
Additional file 2 table S2.
Clinical applications of MacArray™ M-chip
Both cytogenetic analyses and BAC-array CGH were per-
formed for all 94 clinical samples. The overall results are
shown in Additional file 3 table S3. One case showing the
46,XX normal female karyotype failed in the MacArray™
M-chip test because of poor hybridization. Genomic
aberrations were detected in 20 cases (Table 3). Three
balanced rearrangements were identified in only conven-
tional karyotyping. These balanced rearrangements were
two cases of inv[9], which was considered a normal varia-
tion, and one case of translocation, t[8,11].
On the other hand, we identified a microdeletion of the
Yq11.23 region harboring the DAZ gene by MacArray™
M-chip in eight cases, seven showing normal male karyo-Park et al. BMC Medical Genetics 2010, 11:102
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type and one showing trisomy 13. All eight of these cases
were confirmed by FISH (Figure 2). We detected no other
microdeletions in our series.
Discussion
We have developed a targeted low-density BAC-array
DNA chip, the MacArray™ M-chip, as a adjunctive prena-
tal genetic test to conventional karyotyping for simulta-
neous prenatal screening of chromosomal abnormalities
and microdeletion syndromes in South Korea.
The greatest benefit of aCGH is its ability to detect a
very small genomic imbalance that cannot be detected by
conventional G-banded karyotyping. It is also a high-
throughput method, detecting hundreds or thousands of
discrete loci in a single simultaneous assay, in contrast to
FISH and QF-PCR, which have been used for aneuploidy
screening because they give rapid results but only detect
a few loci a time. A microarray DNA chip can be con-
structed using various-sized targets ranging from oligo-
nucleotides (25-85 bp) to BACs (80-200 kb) [15].
Microarrays constructed using a high-resolution and
Table 2: Target Diseases of MacArray™ M-chip
Type Disease  Chromosomal  Location  Gene/marker 
Microdeletion & Duplication ALAGILLE SYNDROME 20p12 JAG1, MKKS, SHGC-79896
ANGELMAN SYNDROME 15q11-q13 UBE3A
CRI-DU-CHAT SYNDROME 5p15.2 TERT
DIGEORGE SYNDROME 22q11.2 TBX1
GLYCEROL KINASE 
DEFICIENCY
Xp21.3-p21.2 GK
KALLMANN SYNDROME 1 Xp22.3 KAL
MILLER-DIEKER 
LISSENCEPHALY SYNDROME
17p13.3 LIS1
MONOSOMY 1p36 
SYNDROME
1p36.33 CDC2L1
MUSCULAR DYSTROPHY, 
DUCHENNE TYPE
Xp21.2, 12q21 DMD
NEUROFIBROMATOSIS, TYPE I 17q11.2 NF1
NEUROFIBROMATOSIS, TYPE II 22q12.2 NF2
PRADER-WILLI SYNDROME 15q11-15q13 SNRPN
SEX-DETERMINING REGION Y Yp11.3 SRY
SMITH-MAGENIS SYNDROME 17p11.2 RAI1
SOTOS SYNDROME 5q35 NSD1
SPERMATOGENIC FAILURE, 
NONOBSTRUCTIVE, Y-LINKED
Yq11.23 DAZ
STEROID SULFATASE 
DEFICIENCY DISEASE
Xp22.31 -
WILLIAMS-BEUREN 
SYNDROME
7q11.2 LIMK1
WOLF-HIRSCHHORN 
SYNDROME
4p16.3 WHSC1
Aneuploidy Trisomy 13 13q12.11~13q33.3 -
Trisomy 18 18p11.32~18q22.3 -
Trisomy 21 21q11.2~21q22.3 -
Abnormal X (X) Xp11.3~Xq28 -
Abnormal X (XXY) Xp11.3~Xq28 -
Abnormal X (XXX) Xp11.3~Xq28 -
Abnormal Y (XYY) Yp11.2~Yq11.23 -Park et al. BMC Medical Genetics 2010, 11:102
http://www.biomedcentral.com/1471-2350/11/102
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Figure 1 Detection of chromosomal aberrations by MACROGEN MacArray™ M-chip . (a) 15q11-15q13 deletion in DNA samples indicating Prad-
er-Willi syndrome was detected by MACROGEN MacArray™ M-chip. The log 2-based test/reference intensity ratios of DNA clones located on chromo-
some 15 were below -0.25, the threshold indicating chromosomal deletion. (b) Another 5q15.2 deletion in the DNA from cri-du-chat syndrome was 
detected. (c) An Xp21.2 deletion indicating Duchenne muscular dystrophy was also detected in the same way. An 12q21 deletion reported previously 
for the same disease was not detected by our platform. (d) Detection of Edward's syndrome (trisomy 18). The aberration was clearly detected by our 
array system.Park et al. BMC Medical Genetics 2010, 11:102
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whole-genome approach can identify very many poly-
morphisms with not only pathogenic deletions/duplica-
tions but also uncharacterized genomic imbalances.
About two thirds of genomic imbalances detected by pre-
natal array CGH have been interpreted as probably
benign and of no clinical significance [12].
In contrast to genome-wide aCGH chips, this targeted
BAC aCGH chip contains clones only for regions with
known clinical significance. While it had lower overall
detection rates than genome-wide arrays, it greatly
reduced the number of benign CNVs and other anoma-
lies of unclear clinical significance that are otherwise
detected [15]. Shaffer et al. [16] reported that 5.6% of
cases showed clinically relevant abnormalities, with only
2.4% and 0.9% showing familial variants and unclear sig-
nificance, respectively. A targeted BAC array might there-
fore be considered more applicable to clinical diagnosis.
Application of arrays to prenatal diagnosis requires
great care because even the detection of a familial variant
raises maternal anxiety. Therefore, ruling out insignifi-
cant CNVs and unclear results is critical. The MacArray™
M-chip is specially designed for prenatal screening of
chromosomal abnormalities that should be detected in
the second trimester of pregnancy. Because the array only
contains 181 clones with characterized clinical relevance,
we greatly reduced the uncertainty of results and also the
cost burden on the patients. In this study, we readily
detected 15 microdeletions and 7 aneuploidies in 132 ref-
erence materials purchased from the Coriell Cell
Resource. However, we identified no CNVs or inconclu-
sive alterations in any of those 132 reference materials
(Additional file 2 table S2). All chromosomal abnormali-
ties found by conventional cytogenetic analysis were also
detected by the MacArray™ M-chip except for the appar-
ently balanced structural abnormalities inv[9] and t[8,11].
The MacArray™ M-chip could not identify aneuploidies
of chromosomes 2, 3, 6, 8, 9, 10, 11, 12, 14, 16 and 19,
which are rarely detected in amniocentesis. However,
Additional clones for those chromosomes will be added
in the next upgraded platform. Our platform also could
not be used to detect triploidy. The array CGH platform
is not appropriate for detecting polyploidy because it is
difficult to separate polyploidy from systematic error (dye
bias)
On the other hand, in eight prenatal cases, the MacAr-
ray™ M-chip successfully identified the microdeletion on
Table 3: Abnormal cases detected by conventional karyotype analysis and MacArray™ M-chip test.
sample No.  Karyotype analysis  MacArray™ M-chip Test 
S008 46,XY,inv(9) (q12q13) arr(1,4,5,7,13,15,17,18,20-22)x2,(XY)x1
S026 46,XY arr Yq11.223(23611993-25573091)x0
S031 46,XY arr Yq11.223(23611993-25573091)x0
S035 46,XX, inv(9)(q12q13) arr(1,4,5,7,13,15,17,18,20-22,X)x2
S044 46,XY,t[8;11](p21;p15.5) arr(1,4,5,7,13,15,17,18,20-22)x2,(XY)x1
S048 47,XX,+21 arr(21)x3
S049 47,XX,+18 arr(18)x3
S052 47,XY,+21 arr(21)x3
S055 47,XY,+21 arr(21x3)
S061 47,XY,+21 arr(21)x3,Yq11.223(23611993-
25573091)x0
S065 47, XX,+21 arr(21x3)
S068 46, XY arr Yq11.223(23611993-25573091)x0
S069 46,XY arr Yq11.223(23611993-25573091)x0
S070 47,XY,+21 arr(21)x3
S073 47,XXY arr(X)x2,(Y)x1
S074 46,XY arr Yq11.223(23611993-25573091)x0
S075 46,XY arr Yq11.223(23611993-25573091)x0
S083 47,XY,+21 arr(21)x3
S086 47,XY,+13 arr(13)x2,Yq11.223(23611993-
25573091)x0
S087 47,XXY arr(X)x2,(Y)x1Park et al. BMC Medical Genetics 2010, 11:102
http://www.biomedcentral.com/1471-2350/11/102
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the long arm of Y chromosome (Yq11) that is considered
to be associated with non-obstructive spermatogenic fail-
ure. Because this is a prenatal diagnostic chip, our pur-
pose is not to detect the DAZ microdeletion prenatally.
The DAZ1 probe represents Yq and was used to identify
Y chromosome aneuploidies such as 47,XXY.
Deletions in the Yq11 region are hard to distinguish
from normal variations in routine cytogenetic analysis
and are usually detected by polymerase chain reaction
(PCR) using short tandem repeat (STR) markers. Four of
the eight microdeletions were inherited from their fathers
and the fetuses were fertilized by intracytoplasmic sperm
injection (ICSI). The deletions in the fathers were identi-
fied by PCR prior to in vitro fertilization procedure (IVF).
We did not perform a paternal Y deletion test in the other
four cases, so we did not know whether the deletion was
inherited. As shown in figure 2, deletions of Yq11 were
confirmed by FISH in all eight cases. In this clinical appli-
cation, we could detect only DAZ microdeletions in addi-
tion to anueploidies.
It would be better to extend this study to many more
samples to explore the incidence of microdeletions and
duplications for the given indications further. We plan to
revise and upgrade the chip so that it will contain more
BAC clones for microdeletion syndromes and subtelo-
meric regions for each chromosome. Of course, we will
apply the chip to many more samples and extend its
usage, and hence be able to discuss the benefits of array
CGH screening in comparison to FISH and QF-PCR.
Conclusions
We have successfully designed and applied a BAC-based
array CGH platform for prenatal diagnosis. Even though
the MacArray™ M-chip contains a very limited number of
clones, this system can provide a highly efficient and
accurate method for the prenatal screening of chromo-
some aneuploidies and microdeletions, making it a clini-
cally useful addition to conventional G-banded
karyotyping.
Figure 2 Confirmation of Yq12 deletion by FISH . (a) The MacArray™ M-chip showed deletions in the Yq region. (b). In a patient with Yq deletion, 
the WCP Y signal (green) was detected but the DAZ locus signal (orange) was absent. (c). Normal male control for Yq12 deletion. The signal for the 
DAZ locus was detected in both chromosome and nucleus.Park et al. BMC Medical Genetics 2010, 11:102
http://www.biomedcentral.com/1471-2350/11/102
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